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proliferation, differentiation and apoptosis. The aim of this study is to characterize the expression of CYP
genes in CD34þ human cord blood hematopoietic stem and early progenitor cells (CBHSPCs) as a ﬁrst
step toward assessment of the potential biological functions of CYP enzymes in regulating the expansion
or differentiation of these cells. CD34þ CBHSPCs were puriﬁed from umbilical cord blood via antibody
afﬁnity chromatography. Purity of CD34þ CBHSPCs was assessed using ﬂuorescence-activated cell
sorting. RNA was isolated from puriﬁed CD34þ CBHSPCs and total mononuclear cells (MNCs) for
RNA-PCR analysis of CYP expression. Fourteen human CYPs were detected in the initial screening with
qualitative RT-PCR in CD34þ CBHSPCs. Further quantitative RNA-PCR analysis of the detected CYP
transcripts yielded evidence for preferential expression of CYP2R1 in CD34þ CBHSPCs relative to
MNCs; and for greater expression of CYP1B1 in MNCs relative to CD34þ CBHSPCs. These ﬁndings
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CYP expression in hematopoietic stem cells 465proliferation and/or differentiation and their potential utility as targets for drugs designed to modulate
CD34þ CBHSPC expansion or differentiation.
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Cytochrome P450 (CYP) enzymes play important roles in the
biotransformation of numerous endogenous compounds as well as
drugs and chemical carcinogens1,2; in humans, 57 functional or
potentially functional CYP genes have been identiﬁed3. CYP
genes show varying degrees of tissue selective expression with
some expressing widely in many tissues, whereas others showing
stringent tissue speciﬁcity. The collection of CYP enzymes
expressed in a given tissue can have a signiﬁcant impact on the
metabolome and biological function of that tissue.
The aim of this study is to identify CYP genes selectively
expressed in human hematopoietic stem and early progenitor cells
(HSPCs). In contrast to the large amounts of data available regarding
CYP expression, regulation and function in the liver and other major
extrahepatic organs such as lung and intestine4, relatively little is
known about the expression and function of CYP genes in stem or
progenitor cells. We speculate that the HSPCs may suppress the
expression of CYP genes that support differentiation, while enhan-
cing the expression of CYP genes that are important for the
maintenance of the pluripotency. CYP enzymes may modulate these
biological functions through metabolism of various endogenous
substrates, such as retinoids, androgens, estrogens, vitamin D, and
bile acids. Therefore, it is worthwhile to identify the CYP genes that
are preferentially expressed in HSPCs, as a ﬁrst step toward
characterization of their possible biological functions in these
important cells and their potential utility as targets for drugs that
are designed to modulate HSPC expansion or differentiation.
Several studies have reported detection of CYP expression in
HSPCs. CYP1B1 and CYP2E1 (mRNA and possibly also protein),
but not CYP2C9 or CYP3A4, were detected in human CD34þ
hematopoietic stem and progenitor cells (496% pure) isolated from
peripheral blood5,6. CYP1B1 mRNA was also detected in human cord
blood-derived CD34þ cells, and its levels were suppressed by
treatment with SR1, an agent that increased ex vivo expansion of
these cells7. In a more recent study, CYP1A1, 2B6, 2E1 and 3A4 were
apparently detected in cord blood-derived CD34þ cells (80–85% pure)
on day 0 of differentiation and they showed time-dependent increases
in expression during differentiation into neuron-like cells, although it
was not clear whether the basal expression on day 0 of differentiation
was in the stem cells or in the contaminating mononuclear cells8.
However, none of these studies determined whether the detected CYPs
were preferentially expressed in the CD34þ cells, and the expression
of the other human CYPs in HSPCs has not been examined.
In this study, we ﬁrst performed a global analysis, using qualitative
RNA-PCR, of all 57 human CYP genes for their possible expression in
CD34þ human cord blood HSPCs (CBHSPCs). Following sequence
validation of the detected CYP transcripts in CD34þ CBHSPCs, we
further compared their expression levels to those in total mononuclear
cells from the same donors using quantitative RNA-PCR. Our results
indicate that CYP2R1 is preferentially expressed in CD34þ CBHSPCs
relative to MNCs, whereas CYP1B1 is more abundantly expressed in
MNCs than in isolated CD34þ CBHSPCs.2. Materials and methods
2.1. Materials
CD34 MicroBead kit, magnetically assisted chemical separation
(MACS) unit, human CD34-PE antibody and mouse IgG2a-PE
antibody were purchased from Miltenyi Biotec (Shanghai, China).
Ficoll solution was purchased from Huajing Bioproduct (Shanghai,
China). Trizol reagent was supplied by Invitrogen (Carlsbad, CA,
USA). Deoxy-ribonucleoside triphosphate (dATP, dCTP, dGTP and
dTTP) for polymerase chain reaction (PCR), Taq polymerase,
MgCl2 and molecular weight standards for electrophoresis
(DL500) were purchased from Sangon Biotech (Shanghai, China).
Ultrapure agarose was supplied by Life Technologies (Paisley, UK).
Oligonucleotide primers were synthesized by BioSune (Shanghai,
China). RNase-free DNase I, PrimeScript II High ﬁdelity RT-PCR
kit and agarose gel DNA extraction kit were supplied by Takara
Biotechnology (Dalian, China). Fast SYBR green master mix was
purchased from Applied Biosystems (Foster City, CA). Other
chemical reagents were purchased from Sigma-Aldrich.
2.2. Preparation of CD34þ CBHSPCs
Anonymous human cord blood donated by pregnant mothers who gave
birth to healthy babies at full term was collected at Suzhou Municipal
Hospital, Suzhou, China. All studies involving human tissue samples
were approved by the local Institutional Review Board. Anticoagulated
cord blood was diluted with phosphate-buffered saline (PBS), and then
subjected to density-gradient centrifugation as described below. Diluted
blood layered on top of a 75% Ficoll solution was centrifuged at 500g,
at 4 1C, for 30 min. MNCs in the interphase were collected and washed
with PBS. Cell numbers were manually counted using a hemacyt-
ometer. CD34þ CBHSPCs were puriﬁed from the MNCs using the
CD34 MicroBead kit with FcR blocking reagent and a MACS unit
based on two-step magnetic bead cell sorting.
Brieﬂy, the MNCs were washed and resuspended in PBS buffer
containing 1% bovine serum albumin and 2 mmol/L edetic acid
(EDTA). Cells were ﬁrst incubated with monoclonal mouse anti-
human CD34 antibodies labeled with MACS microbeads, in the
presence of human IgG as blocking reagent, at 4 1C, for 30 min.
Labeled cells were loaded onto a column installed in a magnetic ﬁeld,
and CD34 cells, which were not conjugated with the microbeads,
were removed as unbound fraction. Trapped CD34þ cells were eluted
after removing the column from the magnet according to the
instructions of the CD34 MicroBead Kit.
2.3. Flow cytometric analysis
The purity and the number of freshly isolated CD34þ CBHSPCs were
assessed via ﬂuorescence-activated cell sorting (FACS) using human
CD34-PE antibody and isotype-matched mouse IgG2a-PE. Cells were
incubated with either antibody at room temperature for 15 min in the
dark. After the incubation, the cells were washed once in PBS. FACS
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with a 488-nm laser. At least 5000 events were acquired to analyze the
abundance of total MNCs or CD34þ CBHSPCs in each sample.
Further analysis was performed to assess the purity of cells after gating
on the MNC region, which was deﬁned based on forward and side
scatter proﬁles. The percentage of CD34þ CBHSPCs among total
MNCs was assessed after correcting for the percentage of cells reactive
with the isotype control IgG2a. Puriﬁed cells were frozen at 80 1C
until used for RNA extraction.
2.4. Isolation of total RNA and cDNA synthesis
Total RNA was isolated from MNCs and CD34þ CBHSPCs using
Trizol reagent according to the manufacturer's instructions. RNA
preparations (10–100 μg) were subsequently incubated with 10 units
of RNase-free DNase I for 30 min at 37 1C in order to remove any
contaminating genomic DNA. RNA quality was assessed spectrally
by the A260/A280 ratio using the One-Drop Spectrophotometer
(Nanodrop, Nanjing, China) and visually following agarose gel
electrophoresis. First-strand cDNA was synthesized with 0.5–1.0 μg
of total RNA using the PrimeScript II High Fidelity RNA-PCR kit.
The reverse transcriptase was omitted in negative control reactions.
2.5. Qualitative RNA-PCR
Each 20-μL ampliﬁcation reaction mixture contained an amount of
reverse transcription (RT) product equivalent to 50 ng of input
RNA, 2 μL of 10 Taq buffer, 3 mmol/L MgCl2, 0.2 mmol/L
(each) dATP, dGTP, dTTP and dCTP, 0.5 μmol/L each primer,
and 2 units of Taq polymerase. Conditions for PCR ampliﬁcation
on a GeneAmp 9700 thermocycler (Applied Biosystems) were as
follows: 3 min of denaturation at 94 1C; 35 cycles of 30 s at 94 1C,
30 s at 56 1C, 30 s at 72 1C; followed by a ﬁnal extension for
5 min at 72 1C. To monitor potential contamination of reagents,
negative control reactions, in which water was used in place of
cDNA, were included with each batch of PCR analysis.
Resected normal, adjacent liver biopsy tissue from an anon-
ymous adult patient with liver cancer was used for RNA
preparation. The liver RNA sample was used as a positive control
for detection of several CYPs using RNA-PCR.
PCR primers (Supplemental Table 1) were designed using source
DNA and RNA sequences obtained from GenBank database. All
primer sets had a calculated annealing temperature of 56 1C. PCR
products were analyzed by agarose gel electrophoresis with ethidium
bromide staining. The bands corresponding to each speciﬁc PCR
product were puriﬁed from the gels using TaKaRa mini BEST agarose
gel DNA extraction kit and further analyzed by DNA sequencing at
Sangon Biotech in order to conﬁrm identity of the PCR products.Table 1 Primers used for quantitative RNA-PCR analysis.a
Gene Primer Sequence (50-30) Pr
CYP1B1 Sense gctgcagtggctgctcct 8
Antisense cccacgacctgatccaattct
CYP2R1 Sense cagcctcatccgagcttc 9
Antisense ccacagttgatatgcctcca
β-actin Sense agagctacgagctgcctgac 11
Antisense cgtggatgccacaggact
aPrimers were designed according to the sequences in GenBank.2.6. Quantitative RNA-PCR
Real-time PCR analyses were carried out using the StepOne-Plus PCR
sytem (Perkin-Elmer Applied Biosystems). Each reaction mixture
(20 μL) contained an amount of RT product equivalent to 100 ng of
input RNA, 0.25 μmol/L each PCR primer (Table 1) and standard
amounts of kit components in the fast SYBR green master mix. The
reaction was monitored for 45 PCR cycles. At the end of the PCR
cycles, melting curve analysis was performed by heating to 95 1C, then
cooling to 65 1C, and ﬁnally heating to 92 1C at 0.2 1C/s. For each
primer pair, RT products were serially diluted, so that an amount of
ﬁrst-strand cDNA equivalent to 1/3 - 1/729 of the initial amount of
total RNA used in the RT step was used to perform quantitative PCR.
Threshold cycle (Ct) values were plotted as a function of input RT-
product amounts (or of the dilution factor of the RT product, as a
surrogate) in order to establish the linear range of PCR ampliﬁcation
for each primer pair and for constructing standard curves. The relative
amounts of CYP1B1 or CYP2R1 mRNAs in two different sample
types (MNCs and CD34þ CBHSPCs) were determined by comparing
to a common set of standard curves and by further normalizing the
results by the amounts of β-actin in the same samples. Standard curves
were constructed using RNA from either MNCs (for genes expressed
at higher levels in MNCs than in CD34þ CBHSPCs) or CD34þ
CBHSPCs (for genes expressed at higher levels in CD34þ CBHSPCs
than in MNCs). No-RT negative controls were routinely included for
each sample.2.7. Data analysis
Statistical signiﬁcance of differences between the two groups was
determined using Student's t-test.3. Results
3.1. Global analysis of CYP mRNA expression in CD34þ
CBHSPCs by RNA-PCR
Initial analysis was focused on identifying those CYP mRNAs that
are detectable in CD34þ CBHSPCs. PCR primers were designed
for each of the 57 potentially functional human CYPs. The puriﬁed
CD34þ CBHSPC preparations from each donor typically con-
tained over 1.5 106 cells, and were more than 94% pure, as
illustrated in Fig. 1. Not all primer pairs used in the initial
screening skipped an intron; therefore, the RNA samples were
treated with RNase-free DNase I to minimize ampliﬁcation of
genomic DNA.oduct size (bp) NCBI accession no. Location
1 NM_000104.3 Exons 2, 3
6 NM_024514.4 Exons 1, 2
4 NM_001101.3 Exons 4, 5
CYP expression in hematopoietic stem cells 467Following several trials to optimize PCR conditions, 14 of the
57 CYPs were consistently detected in puriﬁed CD34þ CBHSPCs
as a single band of expected size, as shown in Fig. 2. TheseFigure 1 Purity of isolated CD34þ CBHSPCs. CD34þ CBHSPCs
were isolated via magnetic bead-based antibody afﬁnity puriﬁcation as
described in Section 2. (A) Scatter diagram of a representative puriﬁed
CBHSPC preparation. Forward scatter (FSC) and side scatter (SSC)
were used to deﬁne gate MNC (the ‘lymphoid gate’). (B) Negative
control. Signal was detected using a PE ﬂuorescence-labeled, isotype-
matched monoclonal mouse IgG2a control antibody. (C) Fractions of
CD34 (M1) and CD34þ (M2) cells within gate MNC. Cells were
incubated with a PE ﬂuorescence-labeled monoclonal mouse anti-
CD34 antibody.included CYP1A1, CYP1B1, CYP2E1, CYP2C18, CYP2C19,
CYP2J2, CYP2R1, CYP2S1, CYP2U1, CYP4F2, CYP4V2,
CYP20A1, CYP27A1 and CYP51A1. Notably, for these CYPs,
the ampliﬁed cDNA sequence did span at least one intron–exon
junction, making it unlikely that they were ampliﬁed from
genomic DNA. Furthermore, in other experiments (data not
shown), the target bands were not detected when reverse tran-
scriptase was omitted during the RT step. The speciﬁcity of the
PCR detection was conﬁrmed by sequencing analysis of the
detected mRNA-derived PCR products; the detected DNA
sequences of the PCR products were 95% to 100% identical to
reference sequences in Genbank (data not shown).
The other 43 human CYPs were not detected in our study under
the conditions used. To validate the primers used, we also
attempted to detect these CYPs in a human liver RNA sample,
used as a positive control. As shown in Fig. 3, 12 of the 43
remaining human CYPs (CYP1A2, CYP2A6, CYP2A7, CYP2B6,
CYP2C9, CYP3A4, CYP3A5, CYP4A22, CYP4F11, CYP4F12,
CYP7B1 and CYP11A1) were detected in the liver, though they
were not detected in CD34þ CBHSPCs in the same experiment.
The remaining 31 CYPs were not detected in either sample (data
not shown). These data served to validate the negative results for
the 12 CYPs that were detected in human liver in this study, while
casting doubt on the validity of the negative results on the
remaining 31 CYPs.3.2. Relative expression levels of the detected CYPs in MNCs
and CD34þ CBHSPCs
Preliminary semiquantitative studies (data not shown) were con-
ducted on three paired samples of CD34þ CBHSPCs
and total MNCs (aliquot saved before puriﬁcation of CD34þ
CBHSPCs). Quantitative RT-PCR was conducted for all 14
detected CYP genes, as well as for CD34 and β-actin (as controls);
but a standard curve was not constructed. The results indicated
that, in each sample, while some CYPs were more abundant,
others were less abundant (when normalized to β-actin) in
MNCs than in CD34þ CBHSPCs. However, when comparing
the results from the three samples, the trend (relative levels in
MNCs vs. CD34þ CBHSPCs) was consistent only for some of the
CYPs, among which CYP2R1 had the greatest enrichment,
whereas CYP1B1 had the least enrichment in the CD34þ
CBHSPCs.
Subsequent studies were focused on determining relative
expression levels of CYP1B1 and CYP2R1 in MNCs and
CD34þ CBHSPCs. A total of ﬁve MNC and CD34þ CBHSPC
samples (each pair from a single donor) were analyzed by
quantitative RNA-PCR. As shown in Fig. 4, the relative mRNA
levels for CYP1B1 (normalized by β-actin levels) were consis-
tently lower (by 0.12-fold) in CD34þ CBHSPCs than in MNCs,
whereas the normalized mRNA levels for CYP2R1 were consis-
tently higher (by about 17-fold) in CD34þ CBHSPCs than in
MNCs. The speciﬁcity of all primers (Table 1) used for the
quantitative RT-PCR was conﬁrmed by melting curve analysis and
by the detection of a single band of expected size on agarose gels
(data not shown). In negative control reactions in which the
reverse transcriptase was omitted during cDNA synthesis, no
signals were detected; Ct values obtained from triplicate reactions
were consistent, and standard curves showed good linearity; the Ct
values of the samples all fell in the linear range of the standard
curves (not shown).
Shuoqi Xu et al.4684. Discussion
To our knowledge, this is the ﬁrst comprehensive analysis of the
expression of human CYP genes in isolated HSPCs. Of the 57
human CYPs, only 14 were speciﬁcally detected by qualitative
RNA-PCR in CD34þ CBHSPCs. Transcripts for 12 other CYP0.0
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Figure 4 Quantitative RT-PCR analysis of CYP1B1 and CYP2R1 in MN
described in Section 2. The relative expression levels of CYP1B1 and CYP
β-actin. The levels in MNCs were arbitrarily set to 1. (***Po0.001, mea
Figure 2 RNA-PCR detection of CYP expression in isolated CD34
(þ) CBHSPCs. PCR was performed with primer pairs shown in
Supplemental Table 1. PCR products (10 μL each) were analyzed on
an ethidium bromide-stained agarose gel. RNA-PCR products of 14
detected CYPs and β-actin (control) are shown. Marker: DL500.
Figure 3 Positive control for selected CYP genes not detected in
CD34(þ) CBHSPCs. RNA from a human liver was used as a positive
control. PCR was performed with primer pairs shown in Supplemental
Table 1. PCR products (10 μL each) were analyzed on an ethidium
bromide-stained agarose gel. Marker: DL500. PCR products of
expected sizes were detected in liver RNA, but not in RNA from
CD34(þ) CBHSPCs.genes, including CYP1A2, CYP2A6, CYP2A7, CYP2B6,
CYP2C9, CYP3A4, CYP3A5, CYP4A22, CYP4F11, CYP4F12,
CYP7B1 and CYP11A1, were not detected in CD34þ CBHSPCs
(though they were detected in the liver as a positive control), a
result indicating that they are not expressed in CD34þ CBHSPCs,
or are expressed at levels below the detection limit of the
experimental conditions used. For the remaining CYP genes, the
data are not conclusive regarding whether they were expressed or
not in the CD34þ CBHSPCs, given the lack of a positive control
for the effectiveness of the PCR assays, even though the PCR
primers were all expected to work. Overall, our data provide the
ﬁrst unequivocal evidence for the presence of transcripts of
multiple CYP genes (CYP2J2, CYP2R1, CYP2S1, CYP2U1,
CYP4F2, CYP4V2, CYP20A1, CYP27A1 and CYP51A1) and
conﬁrm the presence of transcripts for several other CYP genes
(CYP1A1, CYP1B1, CYP2C18, CYP2C19 and CYP2E1) in
puriﬁed preparations of (undifferentiated) human HSPCs.
These results provide the foundation for further studies to
characterize the expression of the corresponding proteins and their
functions.
For the CYP transcripts detected in the puriﬁed CD34þ
CBHSPC preparations, it remained to be conﬁrmed whether they
were expressed in the CD34þ cells or in the small fraction (o6%
of total) of contaminating CD34 MNCs. Due to limitations in
the amounts of RNA samples available from each donor for real-
time PCR analysis, we were not able to resolve this question for all
14 of the detected CYP transcripts. However, we were successful
in demonstrating a large enrichment of the CYP2R1 transcript in
puriﬁed CD34þ CBHSPC preparations compared to total MNCs,
a result strongly supporting the notion that CYP2R1 transcript was
selectively present in the CD34þ stem/progenitor cells. In con-
trast, CYP1B1 transcript was selectively excluded by the cell
isolation process, a result indicating that they were enriched in
CD34 MNCs.
The remarkable and opposing cell speciﬁcity of CYP1B1 and
CYP2R1 mRNA expression in CD34þ CBHSPCs and CD34
MNCs may have interesting implications for possible functions of
these CYP enzymes in hematopoietic stem cell proliferation and/or
differentiation. CYP1B1, which is expressed in a number of
human tissues, can metabolize both xenobiotic (e.g., polycyclic
aromatic hydrocarbons) and endogenous compounds (including
estrogen, retinol, retinal and arachidonic acid)9,10. CYP1B1 is
overexpressed in tumor cells11. Mutations of CYP1B1 have been
linked to the etiology of glaucoma10 and the initiation or
progression of tumorigenesis11. Of particular interest, CYP1B1 isTotal MNCs
CYP2R1
CD34(+)CBHSPCs
* * *
Cs and CD34(þ) CBHSPCs. Quantitative RT-PCR was performed as
2R1 mRNAs in the two sample types were normalized by the levels of
ns7SD; n¼5; Student's t-test).
CYP expression in hematopoietic stem cells 469a target gene for the aryl hydrocarbon receptor; the latter appears
to function as a suppressor of CD34þ CBHSPC expansion7.
CYP2R1, which has not been as intensely studied as CYP1B1
has, appears to have stricter substrate speciﬁcity. It is the major
vitamin D 25-hydroxylase in human liver12. Mutations of CYP2R1
gene were associated with vitamin D deﬁciency. CYP2R1 has also
been detected in extrahepatic tissues, including prostate and
ovarian cancer cells13,14. It is conceivable that CYP2R1, perhaps
through its metabolism of vitamin D or other yet unknown
endogenous substrates, may play an important role in maintaining
the CD34þ CBHSPCs in an undifferentiated and pluripotent state,
whereas CYP1B1 may have an opposite role. Further studies to
test this hypothesis are warranted. Additionally, the differential
expression of CYP1B1 and CYP2R1 also suggests differences in
the expression/function of the nuclear receptors that regulate their
expression; further studies to examine the status of these regula-
tory molecules may also shed light on the functional signiﬁcance
of the differential expression of CYP1B1 and CYP2R1. Conﬁrma-
tion of an important role of one or both of these CYPs in
modulating CD34þ CBHSPC expansion or differentiation would
support their potential utility as drug targets for diseases or
therapies that adversely affect CBHSPCs.
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